BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

2012 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/30/12BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los Angeles on December 5thPrinter Friendly Version
11/14/12BioLineRx Reports Third Quarter 2012 Financial ResultsPrinter Friendly Version
11/12/12BioLineRx to Hold Analyst and Investor Day in New York on December 4, 2012Printer Friendly Version
11/07/12BioLineRx Announces BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual MeetingPrinter Friendly Version
11/05/12BioLineRx to Report Third Quarter 2012 Results on November 14, 2012Printer Friendly Version
10/24/12BioLineRx to Conduct Interim Analysis of Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of SchizophreniaPrinter Friendly Version
10/16/12BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CPrinter Friendly Version
10/09/12BioLineRx Announces New Analysis of EAGLE Phase IIb Study Showing a Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia PatientsPrinter Friendly Version
09/27/12BioLineRx Enters into Share Purchase Agreement with Lincoln Park CapitalPrinter Friendly Version
09/27/12BioLineRx Announces Publication of EAGLE Study Results Demonstrating BL-1020's Efficacy in Improving Cognitive Function in Schizophrenia PatientsPrinter Friendly Version
09/24/12BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020, Extending Patent Protection Until 2031Printer Friendly Version
09/24/12BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020, Extending Patent Protection Until 2031Printer Friendly Version
09/10/12BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten SensitivityPrinter Friendly Version
09/04/12BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological CancersPrinter Friendly Version
08/15/12BioLineRx Reports Second Quarter 2012 ResultsPrinter Friendly Version
08/02/12BioLineRx to Report Second Quarter 2012 Results on August 15, 2012Printer Friendly Version
07/09/12BioLineRx Receives Notice of Intention to Grant Additional European Patent Covering BL-1020, for the Treatment of Schizophrenia Printer Friendly Version
06/13/12Research Underlying BioLineRx's EDP 10, for Treatment of Type 1 Diabetes, Wins Hebrew University's Kaye Award Printer Friendly Version
06/05/12BioLineRx Announces Receipt of Two Notices of Allowance from USPTO for Patents Covering BL-1021, for Treatment of Neuropathic PainPrinter Friendly Version
05/15/12BioLineRx Reports First Quarter 2012 ResultsPrinter Friendly Version
05/08/12BioLineRx to Report First Quarter 2012 Results on May 15, 2012Printer Friendly Version
04/25/12BioLineRx Announces Extension of Patent for BCM (BL-1040) by USPTOPrinter Friendly Version
04/23/12BioLineRx Launches Free Investor Relations App for iPhone Printer Friendly Version
03/28/12BioLineRx to Present at the 2012 Annual Needham Healthcare Conference in New York on April 3rd Printer Friendly Version
03/22/12BioLineRx Reports Fourth Quarter and Calendar 2011 Results Printer Friendly Version
03/07/12BioLineRx Announces Grant of European Patent Covering BL-1020, an Orally Available Treatment for Schizophrenia Printer Friendly Version
03/07/12BioLineRx to Present at the 2012 Annual Roth Growth Conference in Orange County, California on March 14thPrinter Friendly Version
03/05/12BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease Printer Friendly Version
02/29/12BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction Printer Friendly Version
02/28/12BioLineRx Ltd. Announces Closing of $15 Million Private Placement to Institutional InvestorsPrinter Friendly Version
02/21/12BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity Printer Friendly Version
02/16/12BioLineRx to place $15 million in securities with Institutional InvestorsPrinter Friendly Version
02/07/12BioLineRx to present at the BIO CEO & Invvestor Conference Printer Friendly Version
02/06/12BioLineRx In-Licenses Second Oral Hepatitis C TreatmentPrinter Friendly Version
01/24/12BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C Printer Friendly Version
01/03/12BioLineRx Announces Initiation of CE Mark Registration Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction Printer Friendly Version


Interview with Philip Serlin, CEO
December 2016